NNIT A/S is a Danish public IT company that provides IT consultancy, development, implementation and outsourcing of IT services to clients within life sciences in Denmark and internationally as well as to all types of customers in Denmark.Its clients include among others Danish and international life science companies, public organizations, financial institutions and large enterprise companies. As of 2017, NNIT is currently the third-largest IT services provider in Denmark.NNIT's more than 3,000 employees primarily work at the headquarters in Denmark and its offices in Asia, Europe and the USA.The company was founded as Novo Nordisk IT in 1994 through the merger of Novo Nordisk's two existing information technology units. In 1999, Novo Nordisk IT was established as a private limited company, wholly owned by Novo Nordisk. In 2004, the company changed its name to the current NNIT A/S. In March 2015, NNIT was listed on the NASDAQ OMX.The company was founded as Novo Nordisk IT in 1994 through the merger of Novo Nordisk's two existing information technology units.
Competency-based obesity medicine education is critically needed in undergraduate medical training, as emphasized by the Association of American Medical Colleges. Using a competency-based framework, we identified key gaps in obesity education across ten diverse U.S. medical schools. Each institution formed a working group to conduct a gap analysis of the curriculum based on 32 obesity medicine competencies recognized by the obesity medicine fellowship council. The least-addressed domains were Practice-Based Learning and Improvement and Systems-Based Practice, accounting for nine of the ten least-covered competencies. Additional gaps were noted in clinical skills and bias awareness. Most schools were relying on passive teaching methods and limited assessment. Findings highlight opportunities to develop shared, scalable resources to strengthen and standardize obesity medicine education nationwide.
Guidelines recommend combination therapy with glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) for cardiorenal risk reduction in people with type 2 diabetes (T2D); however, there is limited real-world evidence on the long-term effects of combination therapy on cardiometabolic and renal outcomes. The objective of this study was to assess cardiovascular (CV), metabolic, and renal effects of combination therapy with newer generation GLP-1RA (including once-weekly GLP-1RAs, once-daily oral semaglutide, and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] agonists) and SGLT2i compared with SGLT2i alone. This retrospective cohort study included data on US adults with T2D receiving SGLT2i from Komodo’s Healthcare Map from January 1, 2017, to June 30, 2023. The study included 100,455 people in the combination GLP-1RA and SGLT2i group and 339,540 people in the comparison SGLT2i group across 3 cohorts: T2D with atherosclerotic cardiovascular disease (ASCVD), T2D, and T2D with chronic kidney disease (CKD). Entropy balancing was used to balance patient characteristics. Time to first event of ischemic stroke, myocardial infarction (MI), 3-point major adverse cardiovascular event (MACE), and 5-point MACE in T2D with ASCVD cohort were measured. In the T2D cohort, follow-up and change in glycated hemoglobin (HbA1c) and weight, odds of achieving HbA1c < 7
Semaglutide 2.4 mg injection (Wegovy®), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US Food and Drug Administration for weight management in June 2021. Tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, was approved for type 2 diabetes mellitus (T2DM; Mounjaro®) in May 2022 and weight management (Zepbound®) in November 2023. Due to limited data on the long-term effectiveness of these medications, this study assessed real-world weight loss with semaglutide 2.4 mg or tirzepatide after 1 year in patients with overweight or obesity and without T2DM. This retrospective cohort study included adults with overweight or obesity and ≥ 1 pharmacy claim for semaglutide 2.4 mg or tirzepatide in the US Komodo Health database between June 4, 2021, and December 15, 2023. Patients had continuous enrollment for 1 year before (baseline period) and 1 year after (follow-up period) the index date (date of treatment initiation) and persistence on therapy (no gap of > 30 days’ supply) during follow-up. Patients with T2DM at baseline were excluded. Weight change from index to 1 year was descriptively assessed. Overall, 9916 patients were included (semaglutide 2.4 mg, n = 6794; tirzepatide, n = 3122). Baseline characteristics were descriptively similar for semaglutide 2.4 mg and tirzepatide: mean age was 47.8 and 49.5 years, 79.8
AimsThe cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.Materials and methodsA cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).ResultsMean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.LimitationsThe generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.ConclusionsSemaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.
This study compared the effectiveness of semaglutide 2.4 mg vs. no treatment with obesity medication (OM) for reducing weight and improving cardiometabolic risk factors among adults with obesity or overweight. This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024). Patients were matched 1:4 to non-treated patients using a propensity score (PS) model. Change in weight and body mass index (BMI) (primary outcomes) and changes in cardiometabolic risk factors (secondary outcomes; systolic blood pressure [SBP], diastolic blood pressure [DBP], glycated hemoglobin [HbA1c], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) were assessed from baseline to 12 months. PS matching and generalized linear models were used to compare outcomes. A total of 8,857 semaglutide 2.4 mg-treated patients were matched to 35,428 non-treated patients. After matching, baseline characteristics between cohorts were well balanced in mean age (47.6 vs. 47.8 years), mean BMI (36.7 kg/m2 in both cohorts), and gender (76 Semaglutide is a medicine that can help people lose weight and improve other health conditions. In this study, researchers looked at whether adult patients taking semaglutide 2.4 mg (Wegovy®) for 1 year lost weight and improved other health measurements, including cholesterol, triglycerides, and glycated hemoglobin (HbA1c) levels. The study included 8,857 adults treated with semaglutide 2.4 mg and 35,428 adults not treated with obesity medication. The study used information about doctor visits and insurance claims from a large health care database. At the start of the study, all patients had obesity or overweight, and the average age was 48 years. Seventy-seven percent (77
